Welcome to our dedicated page for Onconetix news (Ticker: ONCO), a resource for investors and traders seeking the latest updates and insights on Onconetix stock.
Onconetix, Inc. develops and commercializes biotechnology solutions for men's health and oncology, with Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union, as a core company-specific product. News about ONCO commonly centers on diagnostic commercialization, clinical or regulatory disclosures, operating and financial results, and material agreements tied to its biotechnology business.
Company updates also cover capital-structure actions, including preferred stock and warrant financings, shareholder votes, reverse stock splits, Nasdaq listing compliance matters, and board or executive governance changes.
Oncopeptides AB announced that Holger Lembrer has taken office as Chief Financial Officer (CFO) as of January 18, 2023. His appointment aims to enhance the company’s leadership team, bringing valuable expertise from his previous roles in publicly traded international companies. Oncopeptides focuses on developing therapies for difficult-to-treat hematological diseases, leveraging its proprietary Peptide Drug Candidate platform. Pepaxti, their notable product, has received marketing authorization in the EU and other regions for the treatment of adult patients with multiple myeloma, although it is not currently marketed in the US following a recommendation to withdraw its authorization.